Zachary Smith

Dr. Zachary Smith

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 August 2021 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
PCPradeep S. Chauhan
Pradeep S. Chauhan
KCKevin Chen
Kevin Chen
RBRamandeep K. Babbra
Ramandeep K. Babbra
WFWenjia Feng
Wenjia Feng
NPNadja Pejovic
Nadja Pejovic
ACAadel A. Chaudhuri
Aadel A. Chaudhuri
Background: The standard of care treatment for muscle-invasive bladder cancer (MIBC) is radical cystectomy, which is typically preceded by neoadjuvant chemotherapy. However, the inability to assess minimal residual disease (MRD) noninvasively limits our ability to offer bladder-sparing treatment. Here, we sought to develop a liquid biopsy solution via urine tumor DNA (utDNA) analysis. Methods and findings: We applied urine Cancer Personalized Profiling by Deep Sequencing (uCAPP-Seq), a targeted next-generation sequencing (NGS) method for detecting utDNA, to urine cell-free DNA (cfDNA) samples acquired between April 2019 and November 2020 on the day of curative-intent radical cystectomy from 42 patients with localized bladder cancer. The average age of patients was 69 years (range: 50 to 86), of whom 76% (32/42) were male, 64% (27/42) were smokers, and 76% (32/42) had a confirmed diagnosis of MIBC. Among MIBC patients, 59% (19/32) received neoadjuvant chemotherapy. utDNA variant calling was performed noninvasively without prior sequencing of tumor tissue. The overall utDNA level for each patient was represented by the non-silent mutation with the highest variant allele fraction after removing germline variants. Urine was similarly analyzed from 15 healthy adults. utDNA analysis revealed a median utDNA level of 0% in healthy adults and 2.4% in bladder cancer patients. When patients were classified as those who had residual disease detected in their surgical sample (n = 16) compared to those who achieved a pathologic complete response (pCR; n = 26), median utDNA levels were 4.3% vs. 0%, respectively (p = 0.002). Using an optimal utDNA threshold to define MRD detection, positive utDNA MRD detection was highly correlated with the absence of pCR (p < 0.001) with a sensitivity of 81% and specificity of 81%. Leave-one-out cross-validation applied to the prediction of pathologic response based on utDNA MRD detection in our cohort yielded a highly significant accuracy of 81% (p = 0.007). Moreover, utDNA MRD–positive patients exhibited significantly worse progression-free survival (PFS; HR = 7.4; 95% CI: 1.4–38.9; p = 0.02) compared to utDNA MRD–negative patients. Concordance between urine- and tumor-derived mutations, determined in 5 MIBC patients, was 85%. Tumor mutational burden (TMB) in utDNA MRD–positive patients was inferred from the number of non-silent mutations detected in urine cfDNA by applying a linear relationship derived from The Cancer Genome Atlas (TCGA) whole exome sequencing of 409 MIBC tumors. We suggest that about 58% of these patients with high inferred TMB might have been candidates for treatment with early immune checkpoint blockade. Study limitations included an analysis restricted only to single-nucleotide variants (SNVs), survival differences diminished by surgery, and a low number of DNA damage response (DRR) mutations detected after neoadjuvant chemotherapy at the MRD time point. Conclusions: utDNA MRD detection prior to curative-intent radical cystectomy for bladder cancer correlated significantly with pathologic response, which may help select patients for bladder-sparing treatment. utDNA MRD detection also correlated significantly with PFS. Furthermore, utDNA can be used to noninvasively infer TMB, which could facilitate personalized immunotherapy for bladder cancer in the future.

1 March 2020 in European Urology Focus
Verified
Journal Article
Closed access
RWRyan P. Werntz
Ryan P. Werntz
ZSZachary Smith
Zachary Smith
VPVignesh T. Packiam
Vignesh T. Packiam
NSNorm Smith
Norm Smith
GSGary D. Steinberg
Gary D. Steinberg

1 June 2021 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
GHGrant Henning
Grant Henning
NBNimrod S. Barashi
Nimrod S. Barashi
ZSZachary Smith
Zachary Smith

31 October 2022 in Journal of Robotic Surgery
Verified
Journal Article
Closed access
PDF file
ASAlexander L. Shiang
Alexander L. Shiang
JPJoshua K. Palka
Joshua K. Palka
SBShiva Balasubramanian
Shiva Balasubramanian
RFR. Sherburne Figenshau
R. Sherburne Figenshau
ZSZachary Smith
Zachary Smith
EKEric H. Kim
Eric H. Kim

20 April 2020 in Clinical Genitourinary Cancer
Verified
Journal Article
Closed access
MRMelissa A. Reimers
Melissa A. Reimers
RFRobert S. Figenshau
Robert S. Figenshau
EKEric H. Kim
Eric H. Kim
JTJulie Tucker
Julie Tucker
NKNicole Kasten
Nicole Kasten
JHJames J. Hsieh
James J. Hsieh

30 August 2023 in Translational Oncology
Verified
Journal Article
Open access
CNCayce Nawaf
Cayce Nawaf
ASAlexander Shiang
Alexander Shiang
PCPradeep S. Chauhan
Pradeep S. Chauhan
ACAadel A. Chaudhuri
Aadel A. Chaudhuri
GAGautum Agarwal
Gautum Agarwal
ZSZachary Smith
Zachary Smith
Up to 430,000 cases of bladder cancer are diagnosed each year worldwide. A proposed method for non-invasive monitoring has been to utilize a "liquid biopsy." Liquid biopsy has been proposed as a non-invasive method of testing biomarkers in bodily fluids in order to detect and survey cancer. The liquid biopsy could be utilized to obtain information regarding circulating tumor cells, circulating cell-free tumor DNA, circulating cell-free tumor RNA, and more. It is currently being investigated to help guide adjuvant therapy and improve oncological outcomes. We highlight an array of exciting past and ongoing clinical trials regarding ctDNA and adjuvant therapy in regard to urothelial carcinoma which we believe to be amongst the leaders in the field.